Pain Clinical Trial
Official title:
A Phase III, Randomized, Double-Blind Study of Lactobacillus Brevis CD2 Lozenges Versus Placebo in the Prevention of Acute Oral Mucositis (OM) in Patients With Head and Neck Cancer Receiving Concurrent Radiotherapy and Chemotherapy
RATIONALE: Lactobacillus bevis CD2 lozenge may help prevent symptoms of mucositis, or mouth
sores, in patients receiving radiation therapy and chemotherapy. This therapy may improve the
quality of life of patients with head and neck cancer.
PURPOSE: This phase III trial studies how well Lactobacillus bevis CD2 lozenge prevents oral
mucositis in patients with head and neck cancer who are being treated with cisplatin and
radiation therapy. These results will be compared to results in patients using placebo
lozenges.
OBJECTIVES:
Primary
- To determine whether Lactobacillus brevis CD2 lozenges are effective in reducing oral
mucositis (OM)-related pain in patients undergoing chemoradiotherapy (CRT) for head and
neck squamous cell carcinoma, as measured by the area under the curve (AUC) of Mouth and
Throat Soreness (MTS) score (Oral Mucositis Daily Questionnaire [OMDQ] question 2)
measured daily during CRT and daily for 4 weeks after completion of CRT.
Secondary
- To assess whether L. brevis CD2 lozenges reduce OM as assessed by the provider using the
WHO OM scale, Oral Mucositis Assessment Scale (OMAS), and Common Terminology Criteria
Adverse Events (CTCAE).
- To assess whether L. brevis CD2 lozenges reduce the impact of OM on the ability to
swallow, drink, eat, talk, and sleep, as assessed by the MTS-Activity Limitations
(MTS-AL).
- To assess whether L. brevis CD2 lozenges improve quality of life, as assessed by the
Functional Assessment of Cancer Therapy - Head and Neck (FACT-HN).
- To assess whether L. brevis CD2 lozenges reduce opioid requirements.
- To assess whether L. brevis CD2 lozenges improve radiotherapy compliance.
- To assess whether L. brevis CD2 lozenges reduce weight loss and the need for a feeding
tube.
- To assess whether L. brevis CD2 lozenges affect disease-free survival (DFS) at 12 months
after treatment.
- To evaluate the effect of L. brevis CD2 lozenges on salivary biomarkers, including
metabonomic and inflammatory markers, as measured at baseline, week 3 of CRT, and during
the last week of CRT. (exploratory)
OUTLINE: This is a multicenter, randomized, placebo-controlled, double-blind study. Patients
are stratified according to primary disease site (oral cavity/oropharynx vs nasopharynx vs
hypopharynx/larynx), context of chemoradiotherapy (CRT) (definitive vs post-operative),
cisplatin schedule (every 3 weeks [100 mg/m^2] vs every week [30-40 mg/m^2]), and use of
intensity-modulated radiotherapy (IMRT) (yes vs no). Patients are randomized to 1 of 2
treatment regimens.
- Arm I: Patients dissolve in mouth 1 lozenge of Lactobacillus brevis CD2 every 2-3 hours
(total of 6 per day) daily during CRT (comprising cisplatin and radiotherapy [RT]) and
for 4 weeks after, including weekends.
- Arm II: Patients dissolve in mouth 1 lozenge of placebo every 2-3 hours (total of 6 per
day) daily during CRT and for 4 weeks after, including weekends.
Patients complete questionnaires about their quality of life and pain at baseline and daily
during study treatment.
Saliva is collected from some patients before starting RT, during week 3 of RT, and during
the last week of RT for NMR-spectroscopic metabolomic analysis and future cytokine analysis.
After completion of study treatment, patients are followed up at 12 months.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05559255 -
Changes in Pain, Spasticity, and Quality of Life After Use of Counterstrain Treatment in Individuals With SCI
|
N/A | |
Completed |
NCT04748367 -
Leveraging on Immersive Virtual Reality to Reduce Pain and Anxiety in Children During Immunization in Primary Care
|
N/A | |
Terminated |
NCT04356352 -
Lidocaine, Esmolol, or Placebo to Relieve IV Propofol Pain
|
Phase 2/Phase 3 | |
Completed |
NCT05057988 -
Virtual Empowered Relief for Chronic Pain
|
N/A | |
Completed |
NCT04466111 -
Observational, Post Market Study in Treating Chronic Upper Extremity Limb Pain
|
||
Recruiting |
NCT06206252 -
Can Medical Cannabis Affect Opioid Use?
|
||
Completed |
NCT05868122 -
A Study to Evaluate a Fixed Combination of Acetaminophen/Naproxen Sodium in Acute Postoperative Pain Following Bunionectomy
|
Phase 3 | |
Active, not recruiting |
NCT05006976 -
A Naturalistic Trial of Nudging Clinicians in the Norwegian Sickness Absence Clinic. The NSAC Nudge Study
|
N/A | |
Completed |
NCT03273114 -
Cognitive Functional Therapy (CFT) Compared With Core Training Exercise and Manual Therapy (CORE-MT) in Patients With Chronic Low Back Pain
|
N/A | |
Enrolling by invitation |
NCT06087432 -
Is PNF Application Effective on Temporomandibular Dysfunction
|
N/A | |
Completed |
NCT05508594 -
Efficacy and Pharmacokinetic-Pharmacodynamic Relationship of Intranasally Administered Sufentanil, Ketamine, and CT001
|
Phase 2/Phase 3 | |
Recruiting |
NCT03646955 -
Partial Breast Versus no Irradiation for Women With Early Breast Cancer
|
N/A | |
Active, not recruiting |
NCT03472300 -
Prevalence of Self-disclosed Knee Trouble and Use of Treatments Among Elderly Individuals
|
||
Completed |
NCT03678168 -
A Comparison Between Conventional Throat Packs and Pharyngeal Placement of Tampons in Rhinology Surgeries
|
N/A | |
Completed |
NCT03286543 -
Electrical Stimulation for the Treatment of Pain Following Total Knee Arthroplasty Using the SPRINT Beta System
|
N/A | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT02913027 -
Can We Improve the Comfort of Pelvic Exams?
|
N/A | |
Terminated |
NCT02181387 -
Acetaminophen Use in Labor - Does Use of Acetaminophen Reduce Neuraxial Analgesic Drug Requirement During Labor?
|
Phase 4 | |
Recruiting |
NCT06032559 -
Implementation and Effectiveness of Mindfulness Oriented Recovery Enhancement as an Adjunct to Methadone Treatment
|
Phase 3 | |
Active, not recruiting |
NCT03613155 -
Assessment of Anxiety in Patients Treated by SMUR Toulouse and Receiving MEOPA as Part of Their Care
|